| Literature DB >> 29449938 |
Claas Baier1, Sibylle Haid2, Thomas Pietschmann2, Franz-Christoph Bange1, Andreas Beilken3, Astrid Behnert3, Martin Wetzke4, Richard J P Brown2, Corinna Schmitt5, Ella Ebadi1, Gesine Hansen4, Thomas F Schulz5.
Abstract
Background: Respiratory syncytial virus (RSV) is responsible for upper and lower respiratory tract infection in adults and children. Especially immunocompromised patients are at high risk for a severe course of infection, and mortality is increased. Moreover RSV can spread in healthcare settings and can cause outbreaks. Herein we demonstrate the successful control and characteristics of a RSV outbreak that included 8 patients in our Department of Pediatric Hematology and Oncology.Entities:
Keywords: Cancer patients; Hematology and oncology; Infection control; Molecular typing; Outbreak; Pediatric patients; RSV; Respiratory syncytial virus
Mesh:
Substances:
Year: 2018 PMID: 29449938 PMCID: PMC5812225 DOI: 10.1186/s13756-018-0316-2
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Patients’ characteristics
| Case | Nosocomial (Yes/No) | Agea (years) | Sex (M/F) | Underlying Disease | RSV infection | WBCb (per microliter) | RSV Treatment, Duration (days) | Additional antibiotic treatment | Oxygen (Yes/No) | RSV-related outcome | Virus shedding (days) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | yes | 16 | M | Acute myeloid leukemia (recurrent) | LRTI | 0 | oral Ribavirin, 64 | Yes | Yes | Remission | At least 63 |
| 2 | yes | 15 | M | Severe aplastic anemia | LRTI | 800 | oral Ribavirin, 10 | Yes | Yes | Remission | 7 |
| 3 | Yes | 16 | M | Acute lymphoid leukemia | URTI | 1200 | - | Yes | Yes (at night) | Remission | At least 6 |
| 4c | Yes | 9 | M | Post-transplant Burkitt's leukemia | URTI | 300 | - | Yes | Yes | Remission | 17d |
| 5 | Yes | 1 | F | Neuroblastoma | URTI | 9500 | intravenous Ribavirin, 8 | Yes | Yes | Remission | 44 |
| 6 | Possible | 3 | F | Ewing Sarcoma | URTI | 500 | - | Yes | Yes | Remission | 5 |
| 7 | Yes | 10 | F | Acute lymphoid leukemia | URTI | 700 | - | Yes | No | Remission | 4 |
| 8 | Possible | 14 | F | Acute lymphoid leukemia | URTI | 290 | oral Ribavirin, 8 | Yes | No | Remission | 13 |
aAt time of virus detection
bAt time (+/- 2 days) of virus detection
cOnset of disease after discharge (treatment in home town hospital)
dThere had been no in-house tests between first positive and first negative testing
Fig. 1Epidemic curve for the RSV outbreak
Fig. 2Outbreak timeline. Grey bars indicate the patient’s stay on the ward. ‘X’ indicates positive routine diagnostic RSV testing (DFA, PCR, POCT). ‘O’ indicates a negative routine diagnostic RSV testing. *Case 1 was readmitted on May 6th and had another positive testing on May 9th (not shown)
Fig. 3Highlighter plot depicting nucleotide mismatches comparing the sequence of the strain obtained from patient C1 to all other RSV A strains, and the sequence of the strain obtained from patient C7 to all other RSV B strains. a RSV A and (b) RSV B glycoprotein sequences were aligned using MEGA and depicted as highlighter plot using the highlighter analysis tool [23]. Nucleotide exchanges compared to a reference sequence (C1_18_3 (1) for RSV A and C7_18_3 (1) for RSV B) are depicted in color. Absence of sequence information is depicted as grey bar. A schematic of the RSV G protein with the different domains is depicted on top [modified from [39]]. (1) indicates samples taken exclusively for strain typing at the 18th of March and (2) indicates samples collected for routine viral diagnostics. c RSV-G sequence alignment from other pediatric, non-outbreak patients compared to the references C1 and C7, respectively. d Sequencing chromatograms for RSV B cases. The depicted area is highlighted by * and ** in Figure 3B. Overlying sequence information from different quasispecies detected in the samples are highlighted in a box